



Perma-Fix Medical Chairman to Speak at the National Academies of Sciences, Engineering and Medicine - Nuclear and Radiation Studies Board Committee Meeting in Washington, DC

Atlanta – October 28, 2015 – Perma-Fix Medical S.A. (WAR:PFM), a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI), today announced that Dr. Louis F. Centofanti, Chairman of Perma-Fix Medical, will be speaking on Tuesday, November 3, 2015 at the National Academies of Sciences, Engineering and Medicine - Nuclear and Radiation Studies Board committee meeting in Washington, DC. The topics of discussion will revolve around the state of molybdenum-99 (Mo-99) production and utilization, and progress toward eliminating use of highly enriched uranium. Dr. Centofanti will be speaking about Perma-Fix’s Mo-99 and Technetium-99m (Tc-99m) production program.

Dr. Louis F. Centofanti, Chairman of Perma-Fix Medical, commented, “We appreciate the opportunity to showcase Perma-Fix’s new medical isotope production process at this important event. We believe our process will help solve the worldwide shortages of Tc-99m, is less expensive, and does not require the use of high or low enriched uranium targets. In addition, our technology can be easily deployed around the world using standard research and commercial reactors.”

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

This press release contains “forward-looking statements” which are based largely on the Company's expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company's control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, we believe our process will help solve the worldwide shortages of Tc-99m, is less expensive, and does not require the use high or low enriched uranium; and our technology can be easily deployed around the world using standard research and commercial reactors. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; competitive pressures; our ability to apply and market our new technology; and commercialization of Tc-99m. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

Contacts:

Justyna Gudaszevska or David K. Waldman
Crescendo Communications Europe Sp. z o.o
Tel: (+48 71) 79 11 551 / (+1 212) 671-1021
Email : pfm@crescendo-ir.com

Herbert Strauss-European Investor Relations
herbert@eu-ir.com
+43 316 296 316